Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Maintain Mode for protecting results or creating breathing room during busy seasons
Around 40-50% of GLP-1 users report nausea or bloating in the early stages of treatment, though symptoms should settle in the first 4-8 weeks as the body adapts (2)
The company claims their patches work through transdermal delivery that bypasses your digestive system, delivering ingredients straight into your bloodstream for enhanced bioavailability. According to their marketing, 92.3% of customers report fewer cravings and 82.3% reduce snacking, with effects visible within 4 weeks
Electrolyte & Mineral Content: Rated 5/10 Provides sodium and potassium
Currently available GLP-1 receptor agonists in the UK include: For type 2 diabetes : semaglutide (Ozempic [injection], Rybelsus [oral tablet]), dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia) For weight management : semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) Most GLP-1 medications are administered via subcutaneous injection, with dosing frequencies ranging from daily to once weekly depending on the specific formulation
Retatrutide for the treatment of obesity, obstructive sleep apnea and other conditions (TRIUMPH programme)
